A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.
Also called NCT05466643
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Registry
-
NCT05466643
-
- Other papers using this trial's data
- Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic Drugs
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT05466643. Randomized; quadruple masking; primary purpose treatment. Start 2023-03-17 (actual); primary completion 2024-09-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes Mellitus
- Acronym
- ENHANCE-I
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- DWP16001 0.3mg
- Intervention (Drug)
- DWP16001 Placebo
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct05466643- Content hash
211cdba47cb39d247af2248f4699efa9e89b5a95a54654386cc82648049488d1